[
  {
    "template_id": "TPL-CSP-P1",
    "document_type": "CLI-PROT-P1",
    "name": "Phase 1 Clinical Protocol Template",
    "description": "Standard template for Phase 1 first-in-human studies including SAD/MAD designs",
    "sections": [
      {"title": "Protocol Synopsis", "description": "Brief summary of key protocol elements"},
      {"title": "Introduction", "description": "Background, rationale, and risk/benefit assessment"},
      {"title": "Study Objectives", "description": "Primary, secondary, and exploratory objectives"},
      {"title": "Study Design", "description": "Overall design, population, dosing schedule"},
      {"title": "Safety Assessments", "description": "Safety parameters, stopping rules, AE reporting"},
      {"title": "Statistical Considerations", "description": "Sample size, analysis populations, methods"}
    ],
    "metadata": {
      "phase": "Clinical Phase 1",
      "complexity": "High",
      "estimated_completion_time": "4-6 weeks",
      "typical_length": "50-70 pages"
    }
  },
  {
    "template_id": "TPL-CSP-P2",
    "document_type": "CLI-PROT-P2",
    "name": "Phase 2 Clinical Protocol Template",
    "description": "Template for Phase 2 efficacy studies with placebo control",
    "sections": [
      {"title": "Protocol Synopsis", "description": "Brief summary of key protocol elements"},
      {"title": "Introduction", "description": "Background, rationale, and risk/benefit assessment"},
      {"title": "Study Objectives", "description": "Primary, secondary, and exploratory objectives"},
      {"title": "Study Design", "description": "Overall design, randomization, blinding"},
      {"title": "Efficacy Assessments", "description": "Primary and secondary endpoints"},
      {"title": "Safety Assessments", "description": "Safety parameters, AE reporting"},
      {"title": "Statistical Considerations", "description": "Sample size, interim analyses, methods"}
    ],
    "metadata": {
      "phase": "Clinical Phase 2",
      "complexity": "High",
      "estimated_completion_time": "6-8 weeks",
      "typical_length": "70-90 pages"
    }
  },
  {
    "template_id": "TPL-CSP-P3",
    "document_type": "CLI-PROT-P3",
    "name": "Phase 3 Clinical Protocol Template",
    "description": "Template for pivotal Phase 3 registration studies",
    "sections": [
      {"title": "Protocol Synopsis", "description": "Brief summary of key protocol elements"},
      {"title": "Introduction", "description": "Background, rationale, and risk/benefit assessment"},
      {"title": "Study Objectives", "description": "Primary, secondary, and exploratory objectives"},
      {"title": "Study Design", "description": "Overall design, randomization, blinding"},
      {"title": "Efficacy Assessments", "description": "Primary and secondary endpoints"},
      {"title": "Safety Assessments", "description": "Safety parameters, AE reporting"},
      {"title": "Statistical Considerations", "description": "Sample size, interim analyses, methods"},
      {"title": "Quality Control", "description": "Data monitoring committee, audits"}
    ],
    "metadata": {
      "phase": "Clinical Phase 3",
      "complexity": "High",
      "estimated_completion_time": "8-12 weeks",
      "typical_length": "80-120 pages"
    }
  },
  {
    "template_id": "TPL-IB",
    "document_type": "IB",
    "name": "Investigator's Brochure Template",
    "description": "Comprehensive document for investigators with all relevant product information",
    "sections": [
      {"title": "Summary", "description": "Brief product overview"},
      {"title": "Introduction", "description": "General introduction to the product"},
      {"title": "Physical, Chemical, and Pharmaceutical Properties", "description": "Product characteristics"},
      {"title": "Nonclinical Studies", "description": "Pharmacology, PK, toxicology summaries"},
      {"title": "Effects in Humans", "description": "Clinical PK, safety, efficacy data"},
      {"title": "Summary of Data and Guidance", "description": "Information for investigators"}
    ],
    "metadata": {
      "phase": "Clinical (All Phases)",
      "complexity": "High",
      "estimated_completion_time": "6-8 weeks",
      "typical_length": "100-200 pages"
    }
  },
  {
    "template_id": "TPL-ICF",
    "document_type": "ICF",
    "name": "Informed Consent Form Template",
    "description": "Template for explaining study to participants and documenting consent",
    "sections": [
      {"title": "Introduction", "description": "Study introduction and invitation to participate"},
      {"title": "Purpose", "description": "Study purpose and background information"},
      {"title": "Procedures", "description": "What participation involves"},
      {"title": "Risks and Discomforts", "description": "Potential risks of participation"},
      {"title": "Benefits", "description": "Potential benefits of participation"},
      {"title": "Alternatives", "description": "Alternative treatments or procedures"},
      {"title": "Confidentiality", "description": "Data protection and privacy information"},
      {"title": "Costs/Compensation", "description": "Information about payments and costs"},
      {"title": "Voluntary Participation", "description": "Right to refuse or withdraw"},
      {"title": "Consent Documentation", "description": "Signature fields and witness section"}
    ],
    "metadata": {
      "phase": "Clinical (All Phases)",
      "complexity": "Medium",
      "estimated_completion_time": "2-3 weeks",
      "typical_length": "15-25 pages"
    }
  },
  {
    "template_id": "TPL-SAP",
    "document_type": "CLI-PLAN-SAP",
    "name": "Statistical Analysis Plan Template",
    "description": "Detailed plan for analyzing clinical trial data",
    "sections": [
      {"title": "Introduction", "description": "Study background and objectives"},
      {"title": "Study Design", "description": "Brief description of the trial design"},
      {"title": "Analysis Populations", "description": "ITT, PP, safety populations"},
      {"title": "Analysis Variables", "description": "Endpoint definitions and derivations"},
      {"title": "Statistical Methodology", "description": "Statistical tests and methods"},
      {"title": "Handling of Missing Data", "description": "Approaches for missing data"},
      {"title": "Interim Analyses", "description": "Timing and scope of interim analyses"},
      {"title": "Table, Listing and Figure Shells", "description": "Templates for outputs"}
    ],
    "metadata": {
      "phase": "Clinical (All Phases)",
      "complexity": "High",
      "estimated_completion_time": "3-4 weeks",
      "typical_length": "30-50 pages"
    }
  },
  {
    "template_id": "TPL-CSR",
    "document_type": "CLI-REP-CSR",
    "name": "Clinical Study Report Template",
    "description": "Comprehensive report of clinical trial results (ICH E3 compliant)",
    "sections": [
      {"title": "Synopsis", "description": "Brief summary of study and results"},
      {"title": "Introduction", "description": "Background and rationale"},
      {"title": "Study Objectives", "description": "Primary, secondary objectives"},
      {"title": "Investigational Plan", "description": "Study design and methods"},
      {"title": "Study Patients", "description": "Disposition, demographics, baseline"},
      {"title": "Efficacy Evaluation", "description": "Primary and secondary efficacy results"},
      {"title": "Safety Evaluation", "description": "AEs, labs, vital signs"},
      {"title": "Discussion and Conclusions", "description": "Result interpretation"},
      {"title": "Tables, Figures, and Graphs", "description": "Data presentations"},
      {"title": "Appendices", "description": "Protocol, SAP, patient listings"}
    ],
    "metadata": {
      "phase": "Clinical (All Phases)",
      "complexity": "High",
      "estimated_completion_time": "8-12 weeks",
      "typical_length": "200-500 pages"
    }
  },
  {
    "template_id": "TPL-TOX",
    "document_type": "PRE-REP-TOX",
    "name": "Toxicology Study Report Template",
    "description": "Template for GLP toxicology study reports",
    "sections": [
      {"title": "Summary", "description": "Brief summary of study and findings"},
      {"title": "Introduction", "description": "Study background and rationale"},
      {"title": "Materials and Methods", "description": "Test system, dosing, procedures"},
      {"title": "Results", "description": "Clinical observations, body weights, clinical pathology"},
      {"title": "Gross Pathology", "description": "Macroscopic findings"},
      {"title": "Histopathology", "description": "Microscopic findings"},
      {"title": "Discussion and Conclusions", "description": "Result interpretation and NOAEL"}
    ],
    "metadata": {
      "phase": "Preclinical",
      "complexity": "High",
      "estimated_completion_time": "4-6 weeks",
      "typical_length": "50-100 pages"
    }
  },
  {
    "template_id": "TPL-PK",
    "document_type": "PRE-REP-PK",
    "name": "Preclinical PK Study Report Template",
    "description": "Template for pharmacokinetic study reports",
    "sections": [
      {"title": "Summary", "description": "Brief summary of study and findings"},
      {"title": "Introduction", "description": "Study background and objectives"},
      {"title": "Materials and Methods", "description": "Test system, dosing, bioanalytical methods"},
      {"title": "Results", "description": "Concentration-time profiles, PK parameters"},
      {"title": "Discussion and Conclusions", "description": "PK interpretation and implications"}
    ],
    "metadata": {
      "phase": "Preclinical",
      "complexity": "Medium-High",
      "estimated_completion_time": "3-4 weeks",
      "typical_length": "30-50 pages"
    }
  },
  {
    "template_id": "TPL-CDP",
    "document_type": "CLI-PLAN-CDP",
    "name": "Clinical Development Plan Template",
    "description": "Strategic document outlining the overall clinical program",
    "sections": [
      {"title": "Executive Summary", "description": "Overview of development strategy"},
      {"title": "Target Product Profile", "description": "Desired product characteristics"},
      {"title": "Overview of Prior Knowledge", "description": "Preclinical and clinical summary"},
      {"title": "Development Strategy", "description": "Overall approach and rationale"},
      {"title": "Clinical Studies", "description": "Phase 1-3 study designs and endpoints"},
      {"title": "Regulatory Strategy", "description": "Submission plan and milestones"},
      {"title": "Risk Assessment", "description": "Development risks and mitigations"},
      {"title": "Appendices", "description": "Supporting information"}
    ],
    "metadata": {
      "phase": "Clinical (All Phases)",
      "complexity": "High",
      "estimated_completion_time": "8-12 weeks",
      "typical_length": "50-100 pages"
    }
  },
  {
    "template_id": "TPL-DMF",
    "document_type": "REG-SUB-DMF",
    "name": "Drug Master File Template",
    "description": "Confidential detailed information about facilities, processes, or articles used in manufacturing, processing, packaging, and storing of drug substances",
    "sections": [
      {"title": "Administrative Information", "description": "Contacts, facility information"},
      {"title": "Drug Substance Information", "description": "Chemistry, manufacturing, controls"},
      {"title": "Manufacturing Process Description", "description": "Detailed manufacturing steps"},
      {"title": "Facility Information", "description": "Building and equipment details"},
      {"title": "Environmental Assessment", "description": "Environmental impact information"}
    ],
    "metadata": {
      "phase": "CMC / Regulatory",
      "complexity": "High",
      "estimated_completion_time": "8-12 weeks",
      "typical_length": "100-300 pages"
    }
  },
  {
    "template_id": "TPL-CTA",
    "document_type": "REG-SUB-CTA",
    "name": "Clinical Trial Application Template",
    "description": "Submission package for EU clinical trial authorization",
    "sections": [
      {"title": "Cover Letter", "description": "Application overview and key information"},
      {"title": "Application Form", "description": "Administrative details and contacts"},
      {"title": "Protocol", "description": "Full clinical protocol document"},
      {"title": "Investigator's Brochure", "description": "Information for investigators"},
      {"title": "IMPD", "description": "Investigational Medicinal Product Dossier"},
      {"title": "GMP Documentation", "description": "Manufacturing compliance information"},
      {"title": "Informed Consent", "description": "Patient information and consent forms"}
    ],
    "metadata": {
      "phase": "Regulatory Submission",
      "complexity": "High",
      "estimated_completion_time": "8-12 weeks",
      "typical_length": "varies (multiple documents)"
    }
  },
  {
    "template_id": "TPL-IND",
    "document_type": "REG-SUB-IND",
    "name": "Investigational New Drug Application Template",
    "description": "US FDA submission for clinical trial authorization",
    "sections": [
      {"title": "Cover Letter", "description": "Application overview and key information"},
      {"title": "Form FDA 1571", "description": "IND application form"},
      {"title": "Table of Contents", "description": "Organized listing of all components"},
      {"title": "Introductory Statement", "description": "Brief overview of drug and development"},
      {"title": "General Investigational Plan", "description": "Planned clinical investigations"},
      {"title": "Investigator's Brochure", "description": "Information for investigators"},
      {"title": "Protocol", "description": "Clinical study protocol"},
      {"title": "Chemistry, Manufacturing and Controls", "description": "Product information"},
      {"title": "Pharmacology and Toxicology", "description": "Nonclinical study data"},
      {"title": "Previous Human Experience", "description": "Prior clinical data (if any)"}
    ],
    "metadata": {
      "phase": "Regulatory Submission",
      "complexity": "High",
      "estimated_completion_time": "8-12 weeks",
      "typical_length": "varies (multiple documents)"
    }
  },
  {
    "template_id": "TPL-PBRER",
    "document_type": "PMS-PSUR",
    "name": "PBRER/PSUR Template",
    "description": "Periodic Benefit-Risk Evaluation Report for marketed products",
    "sections": [
      {"title": "Executive Summary", "description": "Key safety findings and actions"},
      {"title": "Introduction", "description": "Product information and reporting period"},
      {"title": "Worldwide Marketing Status", "description": "Approval status by country"},
      {"title": "Actions for Safety Reasons", "description": "Safety-related actions taken"},
      {"title": "Changes to Reference Safety Information", "description": "Label updates"},
      {"title": "Estimated Exposure", "description": "Patient exposure calculations"},
      {"title": "Data in Summary Tabulations", "description": "AE/SAE data summaries"},
      {"title": "Summaries of Safety Findings", "description": "Detailed safety assessments"},
      {"title": "Signal Evaluation", "description": "New safety signals and evaluations"},
      {"title": "Benefit Evaluation", "description": "Efficacy and effectiveness information"},
      {"title": "Benefit-Risk Analysis", "description": "Overall B-R assessment"},
      {"title": "Conclusions", "description": "Final safety conclusions and actions"}
    ],
    "metadata": {
      "phase": "Post-Marketing",
      "complexity": "High",
      "estimated_completion_time": "6-8 weeks",
      "typical_length": "100-300 pages"
    }
  },
  {
    "template_id": "TPL-RMP",
    "document_type": "REG-RMP",
    "name": "Risk Management Plan Template",
    "description": "EU plan for monitoring safety and minimizing risks",
    "sections": [
      {"title": "Part I - Product Overview", "description": "Administrative information"},
      {"title": "Part II - Safety Specification", "description": "Detailed risk identification"},
      {"title": "Module SI - Epidemiology", "description": "Disease epidemiology"},
      {"title": "Module SII - Non-clinical", "description": "Non-clinical findings"},
      {"title": "Module SIII - Clinical Trials", "description": "Exposure and safety from trials"},
      {"title": "Module SIV - Post-Marketing", "description": "Post-approval experience"},
      {"title": "Module SV - Additional Requirements", "description": "Special populations"},
      {"title": "Module SVI - Additional EU Requirements", "description": "EU-specific elements"},
      {"title": "Module SVII - Identified Risks", "description": "Known safety concerns"},
      {"title": "Module SVIII - Summary", "description": "Summary of safety concerns"},
      {"title": "Part III - Pharmacovigilance Plan", "description": "Safety monitoring activities"},
      {"title": "Part IV - Post-Authorization Efficacy Studies", "description": "Efficacy follow-up"},
      {"title": "Part V - Risk Minimization Measures", "description": "Risk reduction activities"},
      {"title": "Part VI - Summary", "description": "Summary of plan"}
    ],
    "metadata": {
      "phase": "Regulatory Submission / Post-Marketing",
      "complexity": "High",
      "estimated_completion_time": "8-12 weeks",
      "typical_length": "150-400 pages"
    }
  },
  {
    "template_id": "TPL-DDPS",
    "document_type": "PMS-DDPS",
    "name": "Detailed Description of Pharmacovigilance System",
    "description": "Corporate PV system description for regulatory authorities",
    "sections": [
      {"title": "QPPV Information", "description": "Qualified Person details and CV"},
      {"title": "Organizational Structure", "description": "PV department organization"},
      {"title": "Sources of Safety Data", "description": "How safety information is collected"},
      {"title": "Computerized Systems", "description": "Databases and tracking systems"},
      {"title": "Processes", "description": "PV process descriptions"},
      {"title": "Quality System", "description": "Quality management of PV activities"},
      {"title": "Performance Indicators", "description": "KPIs for PV system"}
    ],
    "metadata": {
      "phase": "Regulatory / PV",
      "complexity": "Medium-High",
      "estimated_completion_time": "4-6 weeks",
      "typical_length": "50-100 pages"
    }
  },
  {
    "template_id": "TPL-NDA",
    "document_type": "REG-SUB-NDA",
    "name": "NDA/BLA Submission Template",
    "description": "Marketing application for FDA approval (CTD format)",
    "sections": [
      {"title": "Module 1 - Administrative/Prescribing Info", "description": "Regional administrative information"},
      {"title": "Module 2 - CTD Summaries", "description": "Overall summaries and overviews"},
      {"title": "Module 3 - Quality", "description": "CMC information"},
      {"title": "Module 4 - Nonclinical", "description": "Toxicology and pharmacology reports"},
      {"title": "Module 5 - Clinical", "description": "Clinical study reports"}
    ],
    "metadata": {
      "phase": "Regulatory Submission",
      "complexity": "High",
      "estimated_completion_time": "12-18 months",
      "typical_length": "thousands of pages (multiple volumes)"
    }
  },
  {
    "template_id": "TPL-VAL-ASSAY",
    "document_type": "DIS-REP-ASSAYVAL",
    "name": "Assay Validation Report Template",
    "description": "Documentation of analytical method validation",
    "sections": [
      {"title": "Executive Summary", "description": "Brief overview of validation results"},
      {"title": "Introduction", "description": "Method description and validation purpose"},
      {"title": "Materials and Methods", "description": "Reagents, equipment, procedures"},
      {"title": "Validation Parameters", "description": "Tests for specificity, precision, accuracy"},
      {"title": "Results", "description": "Data and calculations for each parameter"},
      {"title": "Acceptance Criteria", "description": "Pass/fail criteria for validation"},
      {"title": "Discussion", "description": "Interpretation of validation results"},
      {"title": "Conclusion", "description": "Overall validation assessment"}
    ],
    "metadata": {
      "phase": "Discovery, Preclinical",
      "complexity": "Medium",
      "estimated_completion_time": "2-3 weeks",
      "typical_length": "30-50 pages"
    }
  },
  {
    "template_id": "TPL-DMPK",
    "document_type": "PRE-REP-PK",
    "name": "DMPK Report Template",
    "description": "Drug metabolism and pharmacokinetics study report",
    "sections": [
      {"title": "Executive Summary", "description": "Key findings and conclusions"},
      {"title": "Introduction", "description": "Study background and objectives"},
      {"title": "Materials and Methods", "description": "Experimental details"},
      {"title": "Results", "description": "PK parameters, metabolism data"},
      {"title": "Discussion", "description": "Interpretation of results"},
      {"title": "Conclusions", "description": "Summary of key conclusions"},
      {"title": "References", "description": "Literature citations"},
      {"title": "Appendices", "description": "Supporting data and calculations"}
    ],
    "metadata": {
      "phase": "Preclinical",
      "complexity": "Medium-High",
      "estimated_completion_time": "3-4 weeks",
      "typical_length": "40-60 pages"
    }
  },
  {
    "template_id": "TPL-LABEL",
    "document_type": "REG-LABEL-US",
    "name": "US Prescribing Information Template",
    "description": "FDA-approved product labeling template in PLR format",
    "sections": [
      {"title": "Highlights of Prescribing Information", "description": "Concise summary"},
      {"title": "Table of Contents", "description": "Organization of full PI"},
      {"title": "1 Indications and Usage", "description": "Approved indications"},
      {"title": "2 Dosage and Administration", "description": "How to use the product"},
      {"title": "3 Dosage Forms and Strengths", "description": "Available forms"},
      {"title": "4 Contraindications", "description": "When not to use"},
      {"title": "5 Warnings and Precautions", "description": "Safety concerns"},
      {"title": "6 Adverse Reactions", "description": "Side effects"},
      {"title": "7 Drug Interactions", "description": "Interactions with other medications"},
      {"title": "8 Use in Specific Populations", "description": "Special populations"},
      {"title": "12 Clinical Pharmacology", "description": "PK/PD information"},
      {"title": "13 Nonclinical Toxicology", "description": "Toxicology information"},
      {"title": "14 Clinical Studies", "description": "Evidence supporting approval"}
    ],
    "metadata": {
      "phase": "Regulatory Submission / Post-Marketing",
      "complexity": "High",
      "estimated_completion_time": "6-8 weeks",
      "typical_length": "20-50 pages"
    }
  }
]